eno101 Antibody

What is eno101 and what cellular functions does it perform?

Eno101 is an alpha-enolase protein expressed in Schizosaccharomyces pombe (fission yeast). While the eno101 antibody specifically targets the yeast protein, it's relevant to understand that alpha-enolase (ENO1 in humans) is a multifunctional protein involved in glycolysis, autoimmunity, fibrinolysis, cell proliferation, and apoptosis . In yeast, eno101 primarily functions as a glycolytic enzyme, catalyzing the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the ninth step of glycolysis. Understanding its role in this model organism may provide insights into conserved enolase functions across species.

What are the technical specifications of commercially available eno101 antibodies?

The commercially available eno101 antibody (e.g., CSB-PA340240XA01SXV) is a rabbit polyclonal antibody raised against recombinant Schizosaccharomyces pombe (strain 972/ATCC 24843) eno101 protein . It is purified using antigen affinity methods and supplied in liquid form with 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative . The antibody has been validated for use in ELISA and Western blot applications and shows reactivity specifically with S. pombe . When ordering this antibody, researchers should be aware of the typical 14-16 week lead time for made-to-order production .

How does the specificity of eno101 antibody compare to other enolase antibodies?

The eno101 antibody is specifically raised against and tested for reactivity with Schizosaccharomyces pombe enolase (eno101) . This specificity contrasts with other enolase antibodies such as those targeting human alpha-enolase (ENO1), which have been extensively studied in contexts like autoimmune diseases and cancer research . While there may be some cross-reactivity between species due to conserved epitopes, researchers should validate any cross-reactivity experimentally if intending to use the eno101 antibody in non-yeast systems. Cross-species reactivity data is particularly important when designing comparative studies or when using yeast as a model system for understanding enolase functions in higher organisms.

How can eno101 antibody be used to investigate stress responses in yeast models?

The eno101 antibody can be employed to track changes in enolase expression and localization during various stress conditions in yeast. Researchers can design experiments using Western blot analysis to quantify expression levels and immunofluorescence microscopy to observe potential redistribution of eno101 under oxidative stress, nutrient deprivation, or temperature shifts. When conducting such experiments, it's important to include appropriate loading controls for Western blots and to collect time-course data to capture dynamic changes.

For subcellular localization studies, researchers should consider both conventional immunofluorescence and advanced techniques such as protein tomography, which allows 3D imaging of protein conformations in situ . This approach can reveal whether eno101 changes its cellular distribution under stress conditions, potentially indicating non-glycolytic functions similar to those observed with ENO1 in mammalian systems, where it can relocate to the cell surface or nucleus under specific conditions .

What considerations should be made when using eno101 antibody in epitope mapping studies?

When using eno101 antibody for epitope mapping, researchers should consider employing multiple complementary approaches. Based on techniques used for other enolase antibodies, researchers might adopt:

• Pepscan technology: This allows systematic analysis of antibody binding to peptide sequences, identifying crucial residues in the epitope .

• Site-directed mutagenesis: By introducing specific amino acid changes in the native protein and testing antibody binding by FACS or other methods, researchers can validate epitope predictions .

• X-ray crystallography: For definitive epitope characterization, crystallizing the antibody Fab fragment with the target protein or peptide provides structural insights into binding orientation and contact residues .

The experience with other enolase antibodies suggests that single amino acid substitutions can dramatically affect binding. For example, in studies with anti-CD20 antibodies, substitutions at position Asn171 completely abolished binding of certain antibodies while being tolerated by others . Similar sensitivity analyses would be valuable for characterizing eno101 antibody binding specificities.

What are the challenges in developing monoclonal antibodies against eno101 compared to polyclonal preparations?

Developing monoclonal antibodies against eno101 presents several research challenges compared to polyclonal preparations. Based on experience with other enolase antibodies, researchers would need to:

• Express and purify high-quality recombinant eno101 protein, potentially using insect cell expression systems similar to those employed for ENO1 monoclonal antibody production .

• Immunize mice with purified eno101 protein, followed by hybridoma technology to generate and screen candidate cell lines .

• Implement rigorous screening protocols to identify clones producing antibodies with desired specificity and functional properties.

The purification process would likely involve caprylic acid-ammonium sulfate precipitation followed by protein A chromatography, with validation by SDS-PAGE to confirm appropriate heavy (~50 kDa) and light chain (~25 kDa) molecular weights .

A significant challenge compared to polyclonal antibodies is epitope restriction - monoclonal antibodies recognize only a single epitope, which may limit their utility if that epitope is poorly accessible in certain experimental contexts. Additionally, producing enough antigen for repeated immunizations and maintaining hybridoma stability during culture can present technical hurdles.

How can comparative studies between eno101 and other enolase isoforms inform evolutionary relationships?

Comparative studies using eno101 antibody alongside antibodies against enolase isoforms from different species can provide insights into evolutionary conservation and divergence of this enzyme family. Researchers could design experiments to:

• Examine cross-reactivity patterns between anti-eno101 and enolases from related yeast species to map epitope conservation.

• Compare subcellular localization patterns across species to identify conserved or divergent compartmentalization.

• Analyze post-translational modifications using immunoprecipitation followed by mass spectrometry to determine how regulatory mechanisms have evolved.

When designing such studies, researchers should carefully consider positive and negative controls to account for potential cross-reactivity artifacts. Sequence alignment analysis prior to experimental work can help identify regions of high conservation or divergence to focus investigation. This approach not only informs evolutionary relationships but can potentially identify species-specific functional adaptations of enolase proteins.

What are the optimal conditions for using eno101 antibody in Western blot applications?

For optimal Western blot results with eno101 antibody, researchers should consider the following protocol parameters:

Sample Preparation:

• Extract proteins under conditions that preserve native structure

• Include protease inhibitors to prevent degradation

• Determine optimal protein loading (typically 20-50 μg of total protein)

Electrophoresis and Transfer:

• Use 10-12% polyacrylamide gels for optimal resolution of eno101 (~47 kDa)

• Transfer to PVDF or nitrocellulose membranes at 100V for 1 hour or 30V overnight

Antibody Incubation:

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Dilute primary eno101 antibody 1:500 to 1:2000 in blocking buffer

• Incubate overnight at 4°C with gentle agitation

• Wash 3-5 times with TBST before adding appropriate HRP-conjugated secondary antibody (anti-rabbit IgG, typically 1:5000-1:10,000)

Detection:

• Use enhanced chemiluminescence (ECL) for detection

• Optimize exposure times based on signal strength

When troubleshooting weak signals, consider increasing antibody concentration, extending incubation time, or using more sensitive detection systems. For high background, more stringent washing and optimized blocking conditions may be necessary.

How should researchers design immunofluorescence studies using eno101 antibody?

When designing immunofluorescence studies with eno101 antibody, researchers should follow this methodological approach:

Sample Preparation:

• Fix cells using 4% paraformaldehyde (10-15 minutes at room temperature) or methanol (-20°C for 10 minutes)

• Permeabilize with 0.1-0.5% Triton X-100 in PBS (5-10 minutes)

• Block with 5% BSA in PBS (1 hour at room temperature)

Antibody Incubation:

• Dilute eno101 antibody 1:100 to 1:500 in blocking buffer

• Incubate samples overnight at 4°C in a humidified chamber

• Wash 3 times with PBS

• Apply fluorophore-conjugated secondary antibody (e.g., goat anti-rabbit IgG conjugated to Alexa Fluor 488 at 1:200)

• Counterstain nuclei with DAPI

Imaging Considerations:

• Use confocal microscopy for precise subcellular localization

• Capture z-stacks to fully analyze three-dimensional distribution

• Include appropriate controls:

  • Secondary antibody only (to assess non-specific binding)

  • Isotype control (to evaluate background)

  • Positive control (known enolase-expressing cells)

For co-localization studies with organelle markers, sequential staining protocols may be necessary to avoid antibody cross-reactivity. Based on protocols used with other enolase antibodies, researchers might consider protein tomography for high-resolution 3D visualization of eno101 complexes in situ .

What are the key considerations for validating eno101 antibody specificity?

Validating antibody specificity is crucial for ensuring reliable experimental results. For eno101 antibody, researchers should implement a multi-faceted validation approach:

Genetic Validation:

• Use eno101 knockout or knockdown strains as negative controls

• Perform rescue experiments with ectopic expression of eno101

• Test reactivity against related yeast strains with varying levels of sequence homology

Biochemical Validation:

• Conduct peptide competition assays where pre-incubation of the antibody with excess immunizing peptide should abolish specific signals

• Perform immunoprecipitation followed by mass spectrometry to confirm target identity

• Test cross-reactivity against purified recombinant related proteins

Technical Validation:

• Compare results across multiple detection methods (Western blot, ELISA, immunofluorescence)

• Evaluate batch-to-batch consistency when using different lots of the antibody

• Include appropriate positive and negative controls in each experiment

The validation strategy should be documented thoroughly, as this information is essential for reproducibility and for troubleshooting if inconsistent results are obtained in subsequent experiments.

How can researchers optimize ELISA protocols using eno101 antibody?

For developing optimized ELISA protocols with eno101 antibody, researchers should consider the following methodological approach:

Protocol Optimization Table:

Based on protocols used for ENO1 antibody testing, researchers should prepare 96-well plates coated with eno101 protein (typically 1 μg/well) overnight at 4°C, followed by blocking with BSA-PBS . Sample dilution series should be prepared to determine the linear range of detection, with incubation times of approximately 2 hours at room temperature for both samples and antibodies .

For optimal chromogenic detection, TMB (3,3',5,5'-Tetramethylbenzidine) substrate provides good sensitivity, with the reaction stopped using 2 mol/L hydrochloric acid . Absorbance should be measured immediately at 450 nm using a plate reader. Standard curves should be included in each assay to allow quantification of samples with unknown concentrations.

How might eno101 antibody be applied in studies of moonlighting protein functions?

The eno101 antibody provides a valuable tool for investigating potential moonlighting functions of enolase in yeast, similar to those observed with ENO1 in higher organisms. Researchers can design experiments to:

• Track changes in subcellular localization under various stress conditions using immunofluorescence microscopy

• Identify novel interaction partners through co-immunoprecipitation followed by mass spectrometry

• Investigate potential surface expression and extracellular functions

When designing such studies, it's essential to consider that moonlighting functions often emerge under specific cellular conditions. For example, ENO1 has been found to play roles in autoimmunity and cancer beyond its canonical glycolytic function. Researchers should design experiments that test eno101 localization and interaction networks under various stress conditions, including nutrient limitation, oxidative stress, and temperature shifts.

The antibody could be particularly valuable in studies comparing wild-type and mutant yeast strains to determine how specific domains of eno101 contribute to its various cellular functions. These studies might provide evolutionary insights into how moonlighting functions developed in the enolase protein family.

What considerations should be made when comparing results between polyclonal eno101 antibody and monoclonal ENO1 antibodies?

When comparing results obtained with polyclonal eno101 antibody to those from monoclonal ENO1 antibodies, researchers should consider several methodological factors:

• Epitope recognition differences: Polyclonal antibodies recognize multiple epitopes, while monoclonal antibodies target a single epitope. This fundamental difference can lead to varying signals in applications like Western blotting or immunohistochemistry .

• Cross-reactivity profiles: Polyclonal eno101 antibody may exhibit cross-reactivity with enolases from other species due to conserved epitopes, whereas monoclonal antibodies typically show higher specificity for their target epitope .

• Sensitivity variations: In some applications, polyclonal antibodies may provide greater sensitivity by binding multiple epitopes on each target molecule, amplifying the signal.

• Batch-to-batch consistency: Monoclonal antibodies generally show higher batch-to-batch consistency compared to polyclonal preparations, which can vary between production lots.

When designing comparative studies, researchers should include appropriate controls and standardization methods to account for these differences. This might include using purified recombinant proteins as standards and performing side-by-side analysis with multiple detection methods to verify consistency of findings.